H1B Report
Side-by-side comparison

ASCENT PHARMACEUTICALS, INC. vs Microsoft Corporation

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
ASCENT PHARMACEUTICALS, INC.
NYRank #FEIN 45-3542806
Entity B
Microsoft Corporation
WARank #5FEIN 91-1144442

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricASCENT PHARMACEUTICALS, INC.Microsoft Corporation
Total filings24372,912
Certified %98.77%94.30%
Denied %0.41%0.15%
Withdrawn %0.82%0.69%
Cert-withdrawn %0.00%4.85%
Rank#5
Active yearsFY2011–FY2026FY2010–FY2026
Worksite stateNYWA

Outcomes — ASCENT PHARMACEUTICALS, INC.

DOL case-status mix.

Outcome breakdown: Certified 98.8%, Withdrawn 0.8%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified98.8%
Withdrawn0.8%
Denied0.4%
Certified98.8%
Withdrawn0.8%
Denied0.4%

Outcomes — Microsoft Corporation

DOL case-status mix.

Outcome breakdown: Certified 94.3%, Cert-withdrawn 4.9%, Withdrawn 0.7%, Denied 0.2%
Outcome breakdown
OutcomeShare
Certified94.3%
Cert-withdrawn4.9%
Withdrawn0.7%
Denied0.2%
Certified94.3%
Cert-withdrawn4.9%
Withdrawn0.7%
Denied0.2%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

ASCENT PHARMACEUTICALS, INC.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20100
FY20112
FY20120
FY201315
FY201422
FY201511
FY201624
FY201757
FY201823
FY201936
FY20200
FY20210
FY20220
FY20230
FY202413
FY202526
FY202614
Microsoft Corporation
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20104,407
FY20114,184
FY20124,005
FY20133,832
FY20143,674
FY20154,476
FY20164,919
FY20174,884
FY20185,457
FY20196,000
FY202051
FY2021110
FY2022150
FY20232,791
FY20249,492
FY20259,362
FY20265,118

Top 5 occupations — ASCENT PHARMACEUTICALS, INC.

Top 5 occupations — Microsoft Corporation

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.